BAIBA

Beta-aminoisobutyric acid (BAIBA) is a small molecule metabolite produced primarily from the catabolism of valine and thymine in skeletal muscle. PMID 37313446 It exists as two enantiomers (R-BAIBA and S-BAIBA), with R-BAIBA being approximately 67 times more abundant in human plasma than S-BAIBA. PMID 31611815

BAIBA functions as a signaling metabolite with multiple biological effects, including regulation of lipid and glucose metabolism, promotion of white adipose tissue browning, enhancement of hepatic fatty acid oxidation, anti-inflammatory properties, and protection against oxidative stress. PMID 37313446PMID 24411942 It acts through several mechanisms, including activation of AMPK signaling and PPARα-mediated pathways. PMID 24411942PMID 31277947PMID 38219388 BAIBA also demonstrates protective effects on bone by preventing osteocyte apoptosis through the Mas-Related G Protein-Coupled Receptor Type D (MRGPRD). PMID 29425508

BAIBA is considered an exerkine (also termed a myokine). PMID 37313446PMID 38219388PMID 29177585PMID 40157803 This classification is supported by several lines of evidence:

• BAIBA is produced and secreted by skeletal muscle during exercise, with plasma levels increasing acutely following aerobic exercise (13% increase in R-BAIBA and 20% increase in S-BAIBA after one hour of exercise at 40% peak power) PMID 31611815
• It is released from myocytes with forced expression of PGC-1α, a key regulator of the exercise response in muscle PMID 24411942
• BAIBA mediates inter-organ communication, acting on distant tissues including adipose tissue, liver, bone, and cardiovascular system to exert systemic metabolic effects PMID 24411942PMID 29177585PMID 28441626
• In humans, plasma BAIBA concentrations are inversely associated with cardiometabolic risk factors PMID 24411942

The molecule has been described as a potential "exercise pill" due to its ability to confer metabolic benefits similar to those of exercise. PMID 37313446

BAIBA has shown therapeutic effects in type 2 diabetes and metabolic disorders. In diabetic mice, oral BAIBA administration reduced blood glucose and lipid levels, attenuated hepatic insulin resistance and lipid accumulation, and reduced hepatic endoplasmic reticulum stress and apoptosis through AMPK-dependent mechanisms. PMID 26907958 These metabolic benefits extend to adipose tissue, where BAIBA attenuated LPS-induced inflammation and insulin resistance in adipocytes, also via AMPK-mediated pathways. PMID 29592806

The compound has been characterized as a signaling metabolite and potential "exercise pill" due to its production during exercise and involvement in regulating lipid, glucose, and bone metabolism, as well as inflammation and oxidative stress. PMID 37313446 BAIBA enhances fatty acid oxidation and reduces body weight through increased leptin production by white adipose tissue. PMID 19735301

Safety data support its therapeutic development. A 90-day subchronic toxicity study in rats established a no-observed-adverse-effect level (NOAEL) of 900 mg/kg/day, with no treatment-related adverse effects observed. PMID 35549583

Additional therapeutic applications have been explored in neuropsychiatric conditions. BAIBA functions as a gliotransmitter that activates GABA-B and group-III metabotropic glutamate receptors, potentially contributing to clozapine's efficacy in treatment-resistant schizophrenia. PMID 37759688

BAIBA has also been investigated as a biomarker in malignancy, with elevated urinary concentrations found in patients with leukemia and non-Hodgkin lymphoma, though this represents diagnostic rather than therapeutic utility. PMID 3652458

Human studies and reviews have identified BAIBA-related metabolites as part of metabolic pathways associated with type 2 diabetes development, further supporting its relevance in metabolic disease therapeutics. PMID 34325838